Literature DB >> 8930437

A cost density analysis of benign prostatic hyperplasia.

S F Lanes1, S Sulsky, A M Walker, J Isen, C E Grier, B E Lewis, N A Dreyer.   

Abstract

We assessed the frequency and cost of care for benign prostatic hyperplasia (BPH) among approximately 165,000 subscribers to Fallon Community Health Plan (FCHP), a group model health maintenance organization located in central Massachusetts. We computed rates of episodes of medical services for BPH using automated utilization files, and we estimated costs using Medicare reimbursement schedules and medication average wholesale prices. We identified 3919 men who visited a physician for BPH from January 1, 1991, until December 31, 1994, during which time they contributed 8336 person-years to the analysis. This population comprises approximately 12% of men at least 40 years old at FCHP. From 1991 to 1994, 696 (18%) men received terazosin, 219 (6%) men underwent a prostatectomy, and 41 (1%) men received finasteride. Men averaged 1.66 office visits per year to a physician for BPH. Most office visits (61%) were to a primary care physician, with 39% of the visits to a urologist. Among patients who received terazosin, the frequency of office visits increased slightly after receiving terazosin, from 2.14 to 2.62 visits per year. Among surgery patients, the frequency of visits declined after prostatectomy, from 6.31 visits per year to 1.67 visits. The individual annual cost rate for BPH care ranged from $25.00 to $25,352.00, with an average of $364.00 per person and a median cost of $126.00. The major components of the overall costs were hospital admissions (35%), terazosin dispensings (29%), and physician office visits (19%), with outpatient hospital care and ambulatory procedures accounting for the remaining 17%. Among men receiving terazosin, the average cost was $1190.00 per person-year, and among patients undergoing prostatectomy, the cost was $2630.00 per person-year. The prostatectomy rate declined by nearly 80% during the study period, while the dispensing rate for terazosin doubled, resulting in an overall decline in the total cost of care for BPH from 1991 to 1994.

Entities:  

Mesh:

Year:  1996        PMID: 8930437     DOI: 10.1016/s0149-2918(96)80055-5

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

Review 1.  Changes in medicare reimbursement: impact on therapy for benign prostatic hyperplasia.

Authors:  Robert F Donnell
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 3.092

2.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 3.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.